Mendaera vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mendaera is developing robotic systems that combine real-time imaging and AI guidance to enable minimally invasive procedures with greater precision and speed; raised $100M in a 2024 Series B led by GV and Bessemer;
About
Mendaera is a San Francisco-based medical technology company developing a new class of robotic systems designed to make minimally invasive procedures faster, more precise, and more accessible across a broader range of clinical settings. The company's platform integrates real-time imaging — including ultrasound and CT fluoroscopy — with AI-powered guidance and robotic actuation to assist clinicians performing needle-based interventions such as biopsies, fluid drainage, nerve blocks, and targeted drug delivery. By automating the most technically demanding aspects of needle placement, Mendaera's system aims to reduce procedure time, decrease complication rates, and enable procedures to be performed at the bedside or in community hospitals rather than exclusively in specialized interventional suites.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.